<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084786</url>
  </required_header>
  <id_info>
    <org_study_id>04-003</org_study_id>
    <secondary_id>MSKCC-04003</secondary_id>
    <nct_id>NCT00084786</nct_id>
  </id_info>
  <brief_title>Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Dose Escalation of ZD1839 (Iressa®) (Days 1 and 2) and Docetaxel (Day 3) Every 3 Weeks in Patients With an Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      their growth. Drugs used in chemotherapy such as docetaxel work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Giving gefitinib with docetaxel may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gefitinib when&#xD;
      given with docetaxel in treating patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of gefitinib when administered with docetaxel in&#xD;
           patients with advanced solid tumors.&#xD;
&#xD;
        -  Determine the safety and efficacy of this regimen in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of gefitinib.&#xD;
&#xD;
      Patients receive oral gefitinib once daily on days 1 and 2 and docetaxel IV over 1 hour on&#xD;
      day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-42 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor&#xD;
&#xD;
          -  Failed standard treatment OR no standard treatment exists&#xD;
&#xD;
          -  Measurable or evaluable indicator lesions&#xD;
&#xD;
          -  No uncontrolled CNS metastases (i.e., any known CNS lesion that is progressive [e.g.,&#xD;
             ≥ 25% growth], symptomatic, and/or requires escalating doses of corticosteroids)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 2.0 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 55 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No recent myocardial infarction&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically active interstitial lung disease&#xD;
&#xD;
               -  Chronic, stable, asymptomatic radiographic changes allowed&#xD;
&#xD;
        Ophthalmic&#xD;
&#xD;
          -  No corneal abnormality&#xD;
&#xD;
          -  No history of dry eye syndrome or ocular surface diseases&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No known severe hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  No unstable systemic disease&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other significant medical history or unstable medical condition&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No sperm donation during and for 3 months after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for metastatic cancer&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy to a major bone marrow-containing area&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior gefitinib or erlotinib&#xD;
&#xD;
          -  No other prior epidermal growth factor receptor tyrosine kinase inhibitors&#xD;
&#xD;
          -  More than 30 days since prior non-approved or other investigational drugs&#xD;
&#xD;
          -  No concurrent administration of any of the following CYP3A4 inhibitors or inducers:&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
               -  Itraconazole&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
               -  Troleandomycin&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
          -  No concurrent drugs that cause significant sustained elevations of gastric pH (pH ≥ 5)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naiyer Rizvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David B. Solit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

